AxoGen

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AxoGen reports robust Q4 earnings, eyes growth through innovation

AxoGen's Q4 2022 performance showcased revenue growth, strong margins, and a focus on market expansion through core accounts.
The company's strengths lie in innovative products, high surgeon adoption rates, and a clear roadmap for future growth.
Challenges include post-COVID segment recovery, referral process acceleration, and balancing expenses with revenue.
Opportunities in rep productivity enhancement, product innovation, and regulatory milestones position AxoGen for continued success and market leadership.

AxoGen reports robust Q1 revenue growth and innovation focus

AxoGen's Q1 performance reflects strong revenue growth and market penetration strategies, supported by innovative product introductions and a clear outlook for future revenue and margin improvements.
While facing challenges in managing expenses and executing facility transitions, AxoGen's focus on niche market segments and commitment to R&D present opportunities for sustained growth and profitability.
Overall, AxoGen's strategic direction, emphasis on product innovation, and dedication to improving patient outcomes position the company well for long-term success and market expansion.

AxoGen reports revenue growth and product expansion in Q2

AxoGen's Q2 performance showed revenue growth, increased active accounts, and new product introductions.
Strengths include focus on Core Accounts, sales efforts, and no supply challenges affecting production.
Challenges include validation delay impacting gross margin and extended BLA submission timeline.
Opportunities lie in upcoming product launches, growth in scheduled procedures, and commitment to patient outcomes.

AxoGen reports robust Q3 growth driven by innovative nerve solutions

AxoGen's Q3 performance reflects strong revenue growth driven by emergent trauma and scheduled procedures, supported by a focus on core accounts and innovative products.
While challenges like a net loss persist, opportunities lie in market expansion, regulatory approvals, and maintaining revenue guidance, positioning the company for future success.
Investors should monitor AxoGen's ability to manage expenses, achieve profitability, and leverage its product innovations to drive sustainable growth and shareholder value.

AxoGen reports robust revenue growth, addresses supply chain challenges

AxoGen's strong revenue growth and product innovation demonstrate resilience and market potential.
While challenges like supply chain disruptions persist, the company's focus on cost management and customer relationships is key.
Opportunities lie in market expansion through new products and sustained revenue growth in the coming year.
Analysts are optimistic about AxoGen's performance and strategic direction, emphasizing the need for operational efficiency.

AxoGen reports revenue growth and innovation drive amidst challenges

AxoGen's Q1 2024 performance reflects revenue growth and strategic focus on core accounts and innovation. While challenges like net losses persist, opportunities lie in upcoming product approvals and enhanced transparency. The company's maintained full-year guidance indicates a positive outlook for revenue and cash flow.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2021.

Axogen, Inc. Reports 2021 First Quarter Financial Results

ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021

AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to support the company's key products, with patients experience reduced pain/improved sensation in trauma, breast recon, and post-surgical pain.

Recovering Trauma Cases Should Highlight AxoGen's Improving Execution

ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer.

Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript

ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020.

Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results

ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February.

Axogen, Inc. to Participate at Upcoming February Investor Conferences

Matson

Workiva

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the benchmark index for the U.S. stock market closed at $3,824.68 on Friday, up by nearly 100% over the past five years through Jan. 8.

A Trio of Fast Growing Revenue Stock Picks

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions

Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings

ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses® celebration. For 2021, the Rose Parade will be held as a televised special in Pasadena, CA on New Year's Day.

Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration

AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement

ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming investor events – the Jefferies Virtual London Healthcare Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum.

Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2020 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020.

Axogen, Inc. Reports Third Quarter 2020 Financial Results

ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report third quarter 2020 financial results on Thursday, October 29, 2020 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020

COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.

AxoGen Struggling Through A Protracted Restructuring

Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors

Axogen, Inc. Appoints Paul G. Thomas to Board of Directors

ALACHUA, Fla., Sept.  25, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP Securities MedTech Bio Summit. Axogen’s presentation during this virtual summit is scheduled for Thursday, October 1, 2020 at 11:00 a.m. ET.

Axogen, Inc. to Present at the JMP Securities MedTech Bio Summit

New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft

Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting

ALACHUA, Fla., Aug.  31, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor Virtual Global Healthcare Conference. The virtual presentation is scheduled for Wednesday, September 16, 2020 at 1:20 p.m. ET.

Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

ALACHUA, Fla., July  29, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity 40th Annual Growth Conference. The virtual presentation is scheduled for Wednesday, August 12, 2020 at 9:00 a.m. ET.

Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft

News for AxoGen Stock (AXGN)